Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.

BACKGROUND The trajectory of liver fibrosis is not well understood in the contemporary era of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) therapy. METHODS We assessed the Enhanced Liver Fibrosis (ELF) score, aspartate transaminase-to-platelet ratio index (APRI) and Fibrosis-4 (FIB-4) in 116 women with HIV/HCV coinfection over a 4-year period. Random-effects linear regression models examined the rate of fibrosis change 1-2 years before starting HCV treatment, within 1 year before starting (peri-HCV treatment), within 1 year after and 1-2 years post-HCV treatment in unadjusted and adjusted models including age, race, and changes from pretreatment of factors that might affect fibrosis (eg, alcohol, integrase strand inhibitor [INSTI] use, waist circumference, CD4 count). RESULTS INSTI use nearly doubled from pre- to peri-HCV treatment. In unadjusted analysis, there was a 3.3% rate of rise in ELF pre-HCV treatment, 2.2% and 3.6% rate of decline during the peri- and 1-year post-HCV treatment period, respectively, followed by a 0.3% rise. Similar findings were observed for APRI and FIB-4. There was little effect on the estimated fibrosis trajectories after adjustment. CONCLUSIONS The apparent lack of decline in biomarkers of liver fibrosis beyond 1 year after HCV cure suggests that continued monitoring of liver fibrosis and interventions to mitigate progression in people with HIV after HCV cure remains essential.

[1]  A. Adimora,et al.  Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women , 2021, AIDS.

[2]  J. Margolick,et al.  Characteristics Of The Macs-Wihs Combined Cohort Study: Opportunities For Research On Aging With Hiv In The Longest Us Observational Study Of HIV. , 2021, American journal of epidemiology.

[3]  Lisa P. Barrett,et al.  Liver fibrosis in HIV-Hepatitis C virus (HCV) co-infection before and after sustained virologic response: what is the best non-invasive marker for monitoring regression? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  K. Sherman,et al.  The enhanced liver fibrosis (ELF)-Index predicts hepatic fibrosis superior to FIB4 and APRI in HIV/HCV infected patients. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Adimora,et al.  Weight Gain Associated with Integrase Stand Transfer Inhibitor Use in Women. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  U. Spengler,et al.  Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection , 2019, HIV medicine.

[7]  R. Fontana,et al.  Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Antinori,et al.  Liver stiffness reduction and serum fibrosis score improvement in HIV/hepatitis C virus‐coinfected patients treated with direct‐acting antivirals , 2018, HIV medicine.

[9]  Shelly C. Lu,et al.  Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals , 2018, World journal of gastroenterology.

[10]  K. Nakao,et al.  Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement , 2017, Hepatic medicine : evidence and research.

[11]  P. Tien,et al.  Sex differences in the association of HIV infection with hepatic steatosis , 2016, AIDS.

[12]  P. Tien,et al.  Association of HIV, Hepatitis C Virus, and Liver Fibrosis Severity With the Enhanced Liver Fibrosis Score. , 2016, The Journal of infectious diseases.

[13]  Asociacion Latinoamericana para el Estudio del Higado EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[14]  V. Soriano,et al.  Liver Fibrosis Progression despite HCV Cure with Antiviral Therapy in HIV–HCV-Coinfected Patients , 2015, Antiviral therapy.

[15]  Tara L. Kieffer,et al.  Successful treatment with telaprevir‐based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis , 2015, Journal of viral hepatitis.

[16]  V. Soriano,et al.  Changes in liver fibrosis in HIV/HCV‐coinfected patients following different outcomes with peginterferon plus ribavirin therapy , 2014, Journal of viral hepatitis.

[17]  V. Vullo,et al.  Molecular Mechanisms of Liver Fibrosis in HIV/HCV Coinfection , 2014, International journal of molecular sciences.

[18]  M. Budoff,et al.  Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study , 2014, The American Journal of Gastroenterology.

[19]  M. Manns,et al.  Biopsy-Controlled Liver Fibrosis Staging Using the Enhanced Liver Fibrosis (ELF) Score Compared to Transient Elastography , 2012, PloS one.

[20]  V. de Lédinghen,et al.  Changes of non‐invasive markers and FibroScan values during HCV treatment , 2009, Journal of viral hepatitis.

[21]  P. Bacchetti,et al.  Estimating Complex Multi-State Misclassification Rates for Biopsy-Measured Liver Fibrosis in Patients with Hepatitis C , 2009, The international journal of biostatistics.

[22]  V. de Lédinghen,et al.  Liver fibrosis on account of chronic hepatitis C is more severe in HIV‐positive than HIV‐negative patients despite antiretroviral therapy , 2008, Journal of viral hepatitis.

[23]  C. Lewis,et al.  Regional Adipose Tissue and Elevations in Serum Aminotransferases in HIV-Infected Individuals , 2008, Journal of acquired immune deficiency syndromes.

[24]  Richard D Moore,et al.  Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults , 2007, AIDS.

[25]  R. Sacco,et al.  Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases , 2007, Journal of viral hepatitis.

[26]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[27]  D. Schuppan,et al.  Serum markers detect the presence of liver fibrosis: a cohort study. , 2004, Gastroenterology.

[28]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.